# Pembrolizumab in Biliary Tract Cancer

> **NCT03260712** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 50 (actual)

## Conditions studied

- Biliary Tract Cancer
- Metastatic Cancer
- Advanced Cancer
- Gallbladder Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03260712
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-07
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-08-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03260712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03260712, "Pembrolizumab in Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03260712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*